Fecal Occult Blood Testing Beliefs and Practices of U.S. Primary Care Physicians: Serious Deviations from Evidence-Based Recommendations
Fecal occult blood testing (FOBT) is an important option for colorectal cancer screening that should be available in order to achieve high population screening coverage. However, results from a national survey of clinical practice in 1999–2000 indicated that many primary care physicians used inadequate methods to implement FOBT screening and follow-up.
To determine whether methods to screen for fecal occult blood have improved, including the use of newer more sensitive stool tests.
Cross-sectional national survey of primary care physicians.
Participants consisted of 1,134 primary care physicians who reported ordering or performing FOBT in the 2006–2007 National Survey of Primary Care Physicians’ Recommendations and Practices for Cancer Screening.
Self-reported data on details of FOBT implementation and follow-up of positive results.
Most physicians report using standard guaiac tests; higher sensitivity guaiac tests and immunochemical tests were reported by only 22.0% and 8.9%, respectively. In-office testing, that is, testing of a single specimen collected during a digital rectal examination in the office, is still widely used although inappropriate for screening: 24.9% of physicians report using only in-office tests and another 52.9% report using both in-office and home tests. Recommendations improved for follow-up after a positive test: fewer physicians recommend repeating the FOBT (17.8%) or using tests other than colonoscopy for the diagnostic work-up (6.6%). Only 44.3% of physicians who use home tests have reminder systems to ensure test completion and return.
Many physicians continue to use inappropriate methods to screen for fecal occult blood. Intensified efforts to inform physicians of recommended technique and promote the use of tracking systems are needed.
- Eddy D. American Cancer Society report on the cancer-related health checkup. CA Cancer J Clin. 1980;30:193–240.
- U.S. Preventive Services Task Force. Guide to Clinical Preventive Services. 2nd ed. Alexandria, VA: International Medical Publishing; 1996.
- Winawer SJ, Fletcher RH, Miller L, et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology. 1997;112:594–642. CrossRef
- Byers T, Levin B, Rothenberger D, Dodd GD, Smith RA. American Cancer Society guidelines for screening and surveillance for early detection of colorectal polyps and cancer: update 1997. American Cancer Society Detection and Treatment Advisory Group on Colorectal Cancer. CA Cancer J Clin. 1997;47:154–60. CrossRef
- U.S. Preventive Services Task Force. Screening for colorectal cancer: recommendation and rationale. Ann Intern Med. 2002;137:129–31.
- Smith RA, Cokkinides V, von Eschenbach AC, et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin. 2002;52:8–22. CrossRef
- Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale—update based on new evidence. Gastroenterology. 2003;124:544–60. CrossRef
- U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:627–37.
- Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology. 2008;134(5):1570–95. CrossRef
- U.S. Cancer Statistics Working Group. United States Cancer Statistics: 1999–2005 Incidence and Mortality Web-based Report. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute; 2009. http://apps.nccd.cdc.gov/uscs/. Accessed February 17, 2010.
- Shapiro JA, Seeff LC, Thompson TD, Nadel MR, Klabunde CN, Vernon SW. Colorectal cancer test use from the 2005 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev. 2008;17:1623–30. CrossRef
- Mandel JS, Church TR, Bond JH, et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000;343:1603–7. CrossRef
- Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:1365–71. CrossRef
- Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472–7. CrossRef
- Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996;348:1467–71. CrossRef
- Nadel MR, Shapiro JA, Klabunde CN, et al. A national survey of primary care physicians’ methods for screening for fecal occult blood. Ann Intern Med. 2005;142:86–94.
- Collins JF, Lieberman DA, Durbin TE, Weiss DG, Veterans Affairs Cooperative Study #380 Group. Accuracy of screening for fecal occult blood on a single stool sample obtained by digital rectal examination: a comparison with recommended sampling practice. Ann Intern Med. 2005;142:81–5.
- Sox HC. Office-based testing for fecal occult blood: do only in case of emergency. Ann Intern Med. 2005;142:146–8.
- Phillips KA, Liang SY, Ladabaum U, et al. Trends in colonoscopy for colorectal cancer screening. Med Care. 2007;45:160–7. CrossRef
- Klabunde CN, Lanier D, Nadel MR, McLeod C, Yuan G, Vernon SW. U.S. primary care physicians’ colorectal cancer screening recommendations and practices, 2006–2007. Am J Prev Med. 2009;37(1):8–16. CrossRef
- DeBourcy AC, Lichtenberger S, Felton S, Butterfield KT, Ahnen DJ, Denberg TD. Community-based preferences for stool cards versus colonoscopy in colorectal cancer screening. J Gen Intern Med. 2007;23(2):169–74. CrossRef
- Allison JE, Sakoda LC, Levin TR, et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst. 2007;99:1462–70. CrossRef
- Zauber AG, Lansdorp-Vogelaar I, Knudsen AB, Wilschut J, van Ballegooijen M, Kuntz KM. Evaluating test strategies for colorectal cancer screening: A decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:659–69.
- American Medical Association. CPT R Changes 2006: An Insider’s View. Chicago, IL.
- Korn EL, Graubard BL. Analysis of Health Surveys. Wiley Series in Probability and Statistics. New York: Wiley; 1999:126–39.
- SAS Institute. SAS/STAT 9.1 User’s Guide. Cary (NC): SAS Institute; 2004.
- Research Triangle Institute. SUDAAN Language Manual, Release 9.0. Research Triangle Park (NC): Research Triangle Institute; 2004.
- Centers for Medicare and Medicaid Services. Colorectal cancer: Preventable, treatable and beatable – Medicare coverage and billing for colorectal cancer screening. Medicare Learning Network Matters SE0710. Accessed at www.cms.hhs.gov/MLNMattersArticles/downloads/SE0710.pdf. Accessed February 17, 2010.
- Baron RC, Rimer BK, Breslow RA, et al. Client-directed interventions to increase community demand for breast, cervical, and colorectal cancers screening. Am J Prev Med. 2008;35(1 Suppl):S34–55. CrossRef
- Task Force on Community Preventive Services. Cancer prevention & control, provider-oriented screening interventions: provider reminders & recall. http://www.thecommunityguide.org/cancer/screening/provider-oriented/reminders.html. Accessed February 17, 2010.
- American College of Obstetricians and Gynecologists. Routine cancer screening. ACOG Committee Opinion No. 356. Obstet Gynecol. 2006;108:1611–3.
- Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: A targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:638–58.
- Cole SR, Young GP, Esterman A, et al. A randomized trial of the impact of new faecal haemoglobin test technologies on population participation in screening for colorectal cancer. J Med Screen. 2003;10:117–22. CrossRef
- Levin B, Brooks D, Smith RA, Stone A. Emerging technologies in screening for colorectal cancer: CT colonography, immunochemical fecal occult blood tests, and stool screening using molecular markers. CA Cancer J Clin. 2003;53:44–55. CrossRef
- Meissner HI, Breen N, Klabunde CN, Vernon SW. Patterns of colorectal cancer screening uptake among men and women in the United States. Cancer Epidemiol Biomarkers Prev. 2006;15:389–94. CrossRef
- Chen X, White MC, Peipens LA, Seeff LC. Increase in screening for colorectal cancer in older Americans: results from a national survey. J Am Geriatr Soc. 2008;56:1511–6. CrossRef
- Jimbo M, Myers RE, Meyer B, et al. Reasons patients with a positive fecal occult blood test result do not undergo complete diagnostic evaluation. Ann Fam Med. 2009;7:11–6. CrossRef
- Rao SK, Schilling TF, Sequist TD. Challenges in the management of positive fecal occult blood tests. J Gen Intern Med. 2009;24(3):356–60. CrossRef
- Winawer SJ, Zauber AG, Fletcher RH, et al. Guidelines for colonoscopy surveillance after polypectomy: A consensus update by the US Multi-Society Task Force on Colorectal Cancer and the American Cancer Society. CA Cancer J Clin. 2006;56:143–59. CrossRef
- Lieberman D, Nadel M, Smith RA, et al. Standardized colonoscopy reporting and data system; report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. Gastrointest Endosc. 2007;6:757–66. CrossRef
- Rossi R, Sosa JA, Aslanian HR. Screening colonoscopy and fecal occult blood testing practice patterns: A population-based survey of gastroenterologists. J Clin Gastroenterol. 2008;42:1089–94. CrossRef
- Fecal Occult Blood Testing Beliefs and Practices of U.S. Primary Care Physicians: Serious Deviations from Evidence-Based Recommendations
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Journal of General Internal Medicine
Volume 25, Issue 8 , pp 833-839
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- colorectal cancer
- cancer screening
- primary care
- quality of care
- fecal occult blood test
- Industry Sectors
- Author Affiliations
- 1. Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Highway, MS K55, Atlanta, GA, 30341, USA
- 2. Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD, USA
- 3. Cancer Control Science Department, American Cancer Society, Atlanta, GA, USA
- 4. Department of Veterans Affairs, Environmental Epidemiology Service, Washington, DC, USA